Reviewed by Sarim Mir, MD — Board-Certified Neurologist, Mir Neurology (Hagerstown & Cumberland, MD)
Key takeaways
- Northwestern University (Feinberg School of Medicine) researchers reported that an already FDA-approved compound showed neuroprotective effects in Parkinson’s laboratory models.
- “Neuroprotection” means protecting brain cells from damage or loss — a goal no Parkinson’s treatment has yet been proven to achieve in people.
- This is early, preclinical research using lab-grown neurons and mouse models — not a treatment you can get today.
- The compound studied, N-acetyl-L-leucine, is FDA-approved for a different rare condition, so this is a “repurposing” idea that still needs human trials.
- Always talk with a neurologist before changing anything about your care.
What changed
In March 2026, researchers at Northwestern University’s Feinberg School of Medicine published findings showing that an FDA-approved compound promoted neuroprotective effects in models of Parkinson’s disease. The work was co-led by PingPing Song, PhD, and Dimitri Krainc, MD, PhD, chair of Neurology, and appeared in The Journal of Clinical Investigation.
The compound, called N-acetyl-L-leucine (NALL), is an amino acid derivative. It was approved by the FDA in 2024 to treat a different rare disorder, Niemann-Pick disease type C. In this new study, scientists tested whether it might also protect the brain cells affected by Parkinson’s. The results were encouraging in the lab — but, importantly, the researchers themselves noted that controlled clinical trials in Parkinson’s disease will be needed before anyone can know whether it helps patients.
Plain-English explainer of the condition
Parkinson’s disease is a brain condition that affects movement and gradually progresses over time. Deep in the brain, special nerve cells (neurons) produce a chemical messenger called dopamine, which helps the body move smoothly and steadily. In Parkinson’s, these dopamine-producing neurons slowly become damaged and die off. As dopamine levels fall, people may develop a tremor, stiff muscles, slower movements, and problems with balance.
One reason Parkinson’s is so challenging is that, by the time symptoms appear, many of these neurons have already been lost. A buildup of a sticky protein called alpha-synuclein is thought to play a key role in harming the cells. Today’s medicines help replace or mimic dopamine to ease symptoms, but they do not stop the underlying loss of neurons. There is currently no cure, and no approved therapy has been proven to halt the disease’s progression.
How it works / what’s different
This is where the idea of neuroprotection comes in. Neuroprotection simply means protecting neurons from injury and death — keeping the brain’s cells alive and healthy for longer. A truly neuroprotective therapy would aim to slow or stop the disease itself, not just smooth out symptoms. That is a major unmet goal in Parkinson’s research, and it is why this Northwestern study drew attention.
In the laboratory, the researchers reported that NALL appeared to help in two ways. First, it activated an enzyme called HTRA1 that can break down toxic clumps of alpha-synuclein — helping clear away protein that damages neurons. Second, it raised levels of a protein called parkin, which supported healthier dopamine handling inside the cells. In short, the compound seemed to both clean up harmful buildup and improve the cells’ dopamine machinery.
It is essential to understand the stage of this work. These findings come from dopamine neurons grown from Parkinson’s patients’ cells and from mouse models — not from people with Parkinson’s. Promising laboratory results do not always carry over to humans, and questions of correct dosing, safety, and real-world benefit can only be answered through carefully designed clinical trials. So while NALL is already FDA-approved for a different condition, it is investigational for Parkinson’s. Please do not seek it out as a Parkinson’s treatment based on this early research.
What this means for you in Hagerstown & Cumberland
For families in Western Maryland living with Parkinson’s, research like this is a reason for measured optimism. The search for neuroprotective treatments — therapies that could actually slow the disease — is one of the most important frontiers in neurology, and studies like Northwestern’s help move the field forward. At the same time, this is early science, and it is not yet something we can prescribe.
At Mir Neurology, Dr. Sarim Mir and our team keep up with emerging research so we can separate genuine progress from premature hope and help you make informed decisions. The most powerful tools available today remain the proven ones: timely diagnosis, an individualized treatment plan, regular follow-up, and supportive care.
Learn more about our Parkinson’s disease care and movement disorders services.
If you have questions about Parkinson’s, your current treatment, or what new research could mean for you, we’re here to talk it through. Call (301) 797-7600 to request an appointment or request an appointment online.
Frequently asked questions
Can I get N-acetyl-L-leucine for Parkinson’s now? Not as a proven Parkinson’s treatment. The compound is FDA-approved for a different rare condition, but for Parkinson’s it is investigational and supported only by early laboratory research. Talk with your neurologist before considering any new supplement or medicine.
What does “neuroprotection” mean? It means protecting brain cells (neurons) from damage and death. A neuroprotective therapy would aim to slow or stop the disease process itself. No Parkinson’s treatment has yet been proven to do this in people.
Does this research mean a cure is coming? No. This is encouraging early science, not a cure or even an approved treatment. Human clinical trials would be needed to learn whether it is safe and effective for Parkinson’s.
This article is for general education and is not a substitute for personalized medical advice; please consult a qualified clinician about your specific situation.
Need to talk to a neurologist about this?
Mir Neurology offers same-week appointments in Hagerstown & Cumberland, MD. No referral needed for most plans.
